The semaglutide controversy, examined honestly

You've read the headlines and you're not sure what to believe

Perhaps you came across a story about celebrities obtaining semaglutide informally, or a news piece linking it to a serious side effect, or a warning about fake pens sold online. It's reasonable to feel unsure. The Wegovy controversy isn't one argument, it's several different ones running in parallel, and they tend to get tangled together in media coverage.

Start here: semaglutide was approved in the UK as Wegovy for weight management following formal NICE appraisal (TA875) and MHRA licensing. The clinical trial programme supporting that approval (including the STEP 1 study, published in the New England Journal of Medicine) showed average weight reductions of around 15% over 68 weeks. That's a robust evidence base. The controversy, such as it is, lives largely outside the licensed route, not within it.

One misconception worth setting down gently: a lot of people assume that because semaglutide has attracted celebrity attention, the medicine itself is somehow unserious. The licence, the prescriber assessment, the monitored titration schedule, none of that changes because a tabloid ran a story. The clinical evidence is the clinical evidence.

Where the concerns deserve more weight is in how the medicine reaches people. The private supply chain varies enormously in quality, and the gap between a rigorously assessed prescription and something bought from a social-media seller is not small, it is, in some documented cases, the difference between a genuine medicine and a fake pen containing insulin.

The supply and off-label crisis that gave semaglutide a bad reputation it didn't entirely earn

The Ozempic shortage is probably the biggest single driver of the semaglutide controversy in the UK. Ozempic (the diabetes formulation) ran short partly because demand for weight-loss use outpaced supply. People with type 2 diabetes found their medicine harder to obtain. That is a real harm, and the anger about it is justified.

Wegovy (the weight-management formulation) has a separate supply pathway, but the public conflation of the two brand names meant the reputational damage spread. The MHRA's Drug Safety Update communications have addressed this clearly, urging clinicians and patients to distinguish between licensed indications and supply channels.

Counterfeiting made things worse. By October 2025, enforcement operations had resulted in the seizure of approximately 20 million doses of illegally traded weight-loss medicines worth around £45m, including the first UK site producing counterfeit tirzepatide pens, raided in Northampton. Fake pens have in some cases contained insulin, which can cause severe hypoglycaemia. The MHRA's advice is consistent: obtain these medicines only through a pharmacy you can verify on the GPhC register, and report suspect sellers via Yellow Card.

At nume, medicines are sourced through the licensed UK supply chain via Novo Nordisk's authorised distribution network. Our GPhC-registered pharmacy (premises number 9012878) can be verified directly on the GPhC register.

Side effects: what the controversy gets right, and where it overstates

Genuine side-effect concerns exist and should be stated plainly. The most common are gastrointestinal (nausea, loose stools, constipation, reflux) typically most pronounced around the time of a dose increase and settling within days to a couple of weeks for most people. These are well-documented in the trial data and in the NHS semaglutide information.

More serious, though less common: in January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting acute pancreatitis. The key symptom to act on is severe, persistent abdominal pain that radiates to the back, with or without vomiting. That warrants urgent medical attention, not a call to a help line. Gallbladder problems, and in rare cases allergic reactions, are also listed in the prescribing information.

What the controversy sometimes overstates is the frequency of these serious events relative to the population taking the medicine. The MHRA monitors this actively through the Yellow Card scheme, and prescribers are required to document the benefit-risk balance for each patient individually. A clinical assessment before every prescription is not bureaucracy for its own sake, it is the mechanism by which people with contraindicating conditions are identified before starting. That's why the path to a legitimate prescription involves a real prescriber reviewing your answers, not an automated sign-off.

For patients who also use oral contraception, there is an additional practical consideration: semaglutide slows gastric emptying, which raises the question of whether the pill is absorbed reliably. Our page on semaglutide and birth control covers what the NHS guidance actually says on this, without speculation.

Cost, access inequality, and whether the NHS debate is fair

A strand of the Wegovy controversy that gets less attention than it should is the access question. NICE recommended semaglutide (TA875) for NHS use within specialist weight management services, with a two-year maximum duration. The waiting lists for those services in many parts of England are long. Private treatment is available, but at a cost most people cannot easily absorb month after month.

That's a systemic problem, not a problem with the medicine. Phased NHS rollout for tirzepatide under NICE TA1026 is underway, and from April 2026 some GP practices can prescribe weight-loss medicines directly under the updated GP contract, a development our Wegovy overview and the NHS England weight-management-injections page explain in more detail. Progress is real, but slow.

For people who are clinically suitable and want to explore the private route with a properly regulated service, speaking to a prescriber is the right starting point. If you have questions about how the medicine works beyond weight loss, our page on whether semaglutide controls blood sugar covers the evidence in plain terms. If you'd like to do that, you can speak to our prescribers through a free consultation, same-day clinical review, no waiting list, no subscription.